Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atopic dermatitis or eczema.

Proteologix’s lead candidate PX128 targets TSLP – currently drawing a lot of attention among drug developers – and IL-13, a well-validated target in atopic dermatitis, asthma, and other ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

A diagnosis of POD should be considered with young female and pediatric patients who do not respond to treatment for presumed rosacea, seborrheic dermatitis, or acne vulgaris. The precise etiology ...

A 28-year-old woman developed allergic contact dermatitis within 6 to 24 hours exclusively after using carmine-containing eyeshadows and lipsticks. She had both a positive patch test result and a ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

While for some individuals with atopic dermatitis (AD), the disease can be controlled with topical treatments, those with moderate-to-severe AD often require systemic therapy for long-term disease ...

The global peptide therapeutics market size was valued at USD 45.43 billion in 2023. It is projected to reach from USD 48.11 ...